Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report

ROS1: gene rearrangements occur in 1% to 2% of NSCLC. Acquired “on-target” mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-li...

Full description

Bibliographic Details
Main Authors: Parvin Begum, PhD, Wanyuan Cui, MBBS, Sanjay Popat, PhD
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
ROS1 fusion
ctDNA
Lorlatinib
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432200100X

Similar Items

Similar Items